Refine by
Cornea Articles & Analysis: Older
27 news found
People with healthy immune systems may develop infections of the nails or cornea. There have even been past investigations by the Centers for Disease Control and Prevention of outbreaks of Fusarium keratitis that were associated with contaminated eye products. ...
(“BRIM,” TPEx 6885) is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye disease which causes very severe cornea damage and can lead to loss of sight. Dr. Haishan Jang, Chairwoman and CEO of BRIM Biotechnology, commented, ...
It stimulates stem cell differentiation, repairs the cornea, inhibits inflammation, and promotes recovery in DED. Phase 2 clinical trial results have shown that BRM421 not only significantly improved DED symptoms including dryness, burning/stinging, and photophobia within one week of treatment, but also showed efficacy in repairing the cornea in 15 days. ...
” BRM421 is a novel, first-in-class regenerative peptide therapy which, if successful, could offer patients full relief of symptoms plus repair the damage to the cornea. BRM421 is derived from BRIM’s proprietary, stem cell regenerative PEDF-derived Short Peptides (PDSPs), which can also be applied across multiple therapy areas and indications. In the treatment of ...
BRM421 is a novel, first-in-class regenerative peptide therapy which, if successful, could offer patients complete relief from dry eye symptoms by stimulating the proliferation and differentiation of stem cells to repair damage to the cornea. BRM421 was developed using BRIM’s proprietary stem cell regenerative Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide ...
Analysis provides further validation of MINIject®’s meaningful and sustained efficacy in open angle glaucoma patients No safety concerns with corneal endothelial health reported across all three trials MINIject® delivers positive, consistent results up to two-year follow-up in patients across Central and South America, Asia and Europe WAVRE, Belgium — 8 June 2022: ...
The functional domain of PEDF chosen to generate PDSPs can be used to treat dry eye disease by speeding up the cornea repair process through stimulation of corneal stem cell proliferation and differentiation, anti-inflammation and meibomian gland recovery.?? ...
ARLINGTON, Mass., May 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported clinical data from a Phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the treatment of severe ocular diseases driven ...
ARLINGTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present data from a previously completed Phase 1b clinical trial of KPI-012 in a poster session at the 2022 Association ...
Glaukos’iLinkpharmaceutical platform consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce a reaction called corneal cross-linking designed to strengthen, stabilize and reshape the cornea. ...
Pivotal trial of MINIject, STAR-V, now initiated in 13 sites across the US Positive feedback from world-leading glaucoma surgeons involved in the trial MINIject is the only commercially available MIGS device targeting the supraciliary space. Commercial rollout continues following European approval in 2021 WAVRE, Belgium — 12 January 2022: iSTAR Medical, a medtech company delivering ...
In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. ...
In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. ...
In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. ...
In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. ...
The FDA clearance is based on data from multiple studies of the TearCare System, including recent safety and effectiveness clinical data from the pivotal OLYMPIA study published in Cornea. At one month post treatment in the OLYMPIA study, patients who received a single TearCare procedure showed significant improvements (P < 0.0001) in mean tear film breakup time and meibomian ...
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced publication in Clinical Ophthalmology of favorable data showing that microinvasive glaucoma surgery (MIGS) using the OMNI® Surgical System suppressed daily fluctuations in intraocular pressure ...
Bio-Tissue, Inc., a TissueTech company and pioneer in the clinical application of human birth tissue allografts to promote regenerative healing for ocular surface disease and disorders, announced today that it has entered into a Vendor Agreement with EyePro Group Purchasing Organization (GPO), LLC. As such, GPO members can now take advantage of membership purchasing volume discounts to access ...
CIS Pharma’s new lens care patent application was published. The patent covers the latest developments in the field of contact lens care creating multi-purpose disinfecting solutions, MPDS, with an improved efficacy/safety profile. CIS Pharma’s innovation reduces the trade-off between efficacy and safety, inherent to MPDS that cover the complete contact lens care regimen with just one ...
Louisiana’s first prosthetic iris implant was performed today at AVALA by Dr. Satya Reddy with Louisiana Cornea Specialists. The CUSTOMFLEX® ARTIFICIALIRIS Veo Ophthalmics implant was used to treat disabling glare as a result of infection over 15 years ago. ...